COMP <GO>
INDV vs JNJ // FORWARD P/E MULTIPLE
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: INDV 5
— JNJ 8
▲ FORWARD P/E MULTIPLE LEADER: INDV
LAST: $35.25 (+1.38%) • MKT CAP: $4.16B
forward-pe
18.4x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | 67.90% | +12.30 | INDV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | 25.50% | +36.70 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | 18.5x | -5.10 | INDV | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 2.97% | -5.21 | JNJ | /fcf-yield <GO> |
| Operating Margin | 21.10% | 34.70% | -13.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 16.90% | 28.50% | -11.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 6.00% | -1.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 5.59 | -2.46 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 62.1 | -10.90 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.4x | 23.0x | -4.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.16B | $662.49B | -$658.33B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | JNJ REV | INDV GROSS % | JNJ GROSS % | INDV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $94.19B | 80.2% | 67.9% | -$93.0M | $19.70B |
| FY 2024 | $1.19B | $88.82B | 80.6% | 69.1% | $7.0M | $19.84B |
| FY 2023 | $1.09B | $85.16B | — | — | -$349.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
JNJ // BETA 1.08